Atrial Fibrillation Clinical Trial
— ICE-TEEOfficial title:
Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography for Imaging of the Left Atrial Appendage and Right Atrial Appendage in Patients With Atrial Fibrillation
The presence of intracardiac thrombi and their propensity for systemic embolism is a major
concern in patients with atrial fibrillation (AF) and atrial flutter (AFL) undergoing
cardioversion and ablation procedures. Transesophageal echocardiography (TEE) is the
clinical gold standard imaging modality for visualization of the right atrial appendage
(RAA) and left atrial appendage (LAA) for detection of thrombi as well as risk factors
associated with thrombus formation, including spontaneous echo contrast and low LAA
velocity. However, TEE is a moderately invasive procedure that incurs additional risk, cost,
and patient discomfort. In addition, thrombus detection via TEE may be ambiguous, and
another tool capable of confirming uncertain TEE findings is desirable. This is particularly
crucial in cases when adequate LAA imaging cannot be acquired or if TEE is clinically
contraindicated, requiring alternative imaging modalities that can visualize these
structures.
Phased-array intracardiac echocardiography (ICE) provides high-imaging resolution and is
routinely used during atrial fibrillation (AF) ablation procedures for transseptal puncture
and periprocedural catheter visualization. A majority of imaging acquired during AF ablation
is performed with the ICE catheter in the right atrium (RA). However, these standard views
are often unable to provide sufficient visualization of the LAA structure due to the
relatively long distance between the ICE catheter and LAA.
Placement of the ICE catheter in the pulmonary artery (PA) provides improved visualization
of the LAA over other locations by reducing the anatomic distance between the imaging
catheter and structure of interest. Recent retrospective studies have confirmed improved
assessment of the LAA with ICE imaging from the PA and equivocal sensitivity and specificity
when compared with TEE for evaluation of LAA thrombus. However, these studies did not
systematically evaluate the presence of SEC, flow velocity, the LAA dimensions, or the RAA.
Although these studies support the use of ICE imaging from the PA to clarify or confirm TEE
findings, a prospective and blinded study evaluating both the LAA and RAA in its entirety is
required. We hypothesize that this prospective and blinded study will confirm ICE as
non-inferior to TEE in the assessment of LAA and RAA structure and for the detection of
thrombi.
Status | Completed |
Enrollment | 70 |
Est. completion date | May 2014 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients able to understand and critically review the informed consent. - Patients presenting for an AF and/or AFL ablation procedure who have clinical indication for TEE and ICE. Exclusion Criteria: - Patients in whom placement of an ICE catheter for adequate atrial visualization is technically not feasible. - Patients requiring urgent cardioversion. - Patients with a contraindication for TEE - Inability to give informed consent. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Elad Anter | Biosense Webster, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Presence or absence of RAA and LAA intracardiac thrombi | The right atrial appendage (RAA) and left atrial appendage (LAA) will be assessed for the presence or absence of intracardiac thrombi with the Siemens AcuNav Ultrasound catheter. This is also performed with the standard of care modality, transesophageal echocardiography (TEE) with both operators blinded to the opposing imaging modality. The presence of LAA thrombi requires cancellation of the clinical procedure. After a determination has been made by both operators regarding the presence or absence of thrombi will investigators be unblinded to the opposing imaging modality result. If intracardiac thrombi was detected, the procedure was cancelled according to standard clinical guidelines and practice. There is no follow-up data collected. | Time of Clinical Procedure Only (Enrollment) | Yes |
Secondary | Doppler flow velocity of RAA and LAA | Doppler flow velocity of the right atrial appendage (RAA) and left atrial appendage (LAA) will be measured with the Siemens AcuNav Ultrasound catheter. This is then recorded for offline assessment and comparison to standard of care measurements obtained with Transesophageal Echocardiogram (TEE). This is obtained at the time of the clinical procedure and analyzed offline. There is no follow-up data collected. | Time of Clinical Procedure Only (Enrollment) | No |
Secondary | LAA and RAA anatomical dimensions | The anatomical width (centimeters) length (centimeters), and area (centimeters squared) of the right atrial appendage (RAA) and left atrial appendage (LAA) will be measured with the Siemens AcuNav Ultrasound catheter offline and compared to measurements obtained with Transesophageal Echocardiogram (TEE). There is no follow-up data collected. | Time of Clinical Procedure Only (Enrollment) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |